The ABC of SEIS/EIS Funding for Biotech Startups: A Step-by-Step Guide

Introduction: Your Quick-Start to SEIS/EIS Success

Biotech startups are the epitome of high risk and high reward. You need capital for lab work, clinical trials and stringent approvals before you even think about revenue. That’s where biotech SEIS funding and EIS schemes step in, acting like financial lifelines with serious tax incentives. From seed reliefs to deferral options, they can transform investor appetite and convince early backers that your lab bench is worth the leap. Ready to streamline your fundraising? Revolutionising biotech SEIS funding with Oriel IPO

In this guide, we’ll break down the UK’s Seed Enterprise Investment Scheme (SEIS) and Enterprise Investment Scheme (EIS). You’ll learn eligibility checks, application steps, common pitfalls and best practices. Plus, discover how the Oriel IPO platform’s commission-free model and curated SEIS/EIS marketplace helps you connect with the right angels and VCs—without handing over a chunk of your raise. Let’s dive in and map out your path from lab to launch.

Understanding SEIS and EIS: A Quick Primer

Before you tackle the paperwork, nail down what SEIS and EIS really offer:

• Tax Reliefs
• SEIS: Up to 50% income tax relief on investments up to £100k per tax year.

• EIS: Up to 30% relief on investments up to £1m (or £2m if at least £1m goes into knowledge-intensive companies).

• Capital Gains Advantages

• Exemption on gains from qualifying shares held for the required period.

• Deferral relief: Defer CGT on other assets by investing in EIS shares.

• Investor Appeal

• Lower net risk attracts angels and smaller funds.
• Combined SEIS/EIS rounds can crank up investor confidence.

Both schemes carry rules on company age, trading activities, share classes and maximum gross assets. Familiarise yourself with HMRC’s guidelines to avoid nasty surprises down the line.

Step 1: Checking Your Eligibility

To secure biotech SEIS funding, your startup must tick several boxes:

1. Qualifying Trade
   – Must be a trading company (not a secondary or financial activity).
   – Exclude non-commercial R&D subsidiaries.

2. Gross Asset Limit
   – SEIS: Up to £200k before investment.
   – EIS: Up to £15m before, no more than £16m after.

3. Employee Cap
   – SEIS: No more than 25 full-time employees.
   – EIS: Up to 250 employees.

4. Trading Period
   – SEIS: Company trading for less than 2 years.
   – EIS: Trading for less than 7 years (10 years for knowledge-intensive).

5. Advance Assurance
   – Optional but highly recommended.
   – HMRC pre-checks your plan and issues a green light before you start.

Tip: Get a chartered accountant or specialist adviser to review your business model against SEIS/EIS criteria. It saves time and ups your success rate.

Step 2: Structuring Your Company

Your share structure and valuation have to play by SEIS/EIS rules. Here’s how to set up shop:

• Single Class Shares
  Preferred or ordinary shares? Ordinary shares often work best for SEIS/EIS, as they avoid preferential entitlements.

• Valuation Matters
  HMRC reviews your valuation to prevent overpricing.

• Keep your pre-money valuation modest (alignment with market comparables helps).

• Document R&D spend, IP assets and any grants.

• Articles of Association

• Include SEIS/EIS compliance clauses.
• Ensure no exit-linked bonuses or share buy-backs that conflict with scheme rules.

Solid structure reduces HMRC queries and lets investors claim relief sooner.

Step 3: Applying for Advance Assurance

Advance assurance isn’t a formal requirement but it’s your fail-safe:

1. Prepare Documentation
   – Business plan with R&D roadmap.
   – Full financial projections.
   – Details of share class and valuation justification.

2. Submit to HMRC
   – Use the corporation tax online portal.
   – Expect 4–6 weeks turnaround.

3. Address Feedback
   – HMRC may ask for clarifications.
   – Respond quickly to keep timelines tight.

Expert tip: Consider external grant-writing consultants for R&D grant applications and advance assurance prep. They know the “make or break” details.

Step 4: Listing and Raising Capital

Once you have assurance, it’s time to find investors. You can approach:

• Angel networks
• Specialist biotech VCs
• Corporate Venture Capital
• Crowdfunding platforms that vet for SEIS/EIS eligibility

Platforms like Oriel IPO streamline the process by vetting opportunities in advance. They also help you:

• Showcase your pitch to a curated pool of SEIS/EIS-focused investors.
• Keep 100% of your raise thanks to a transparent subscription fee model.
• Access educational webinars on term sheets and due diligence.

That’s the smart way to launch your SEIS/EIS funding round. Start your biotech SEIS funding journey today

Choosing the Right Investors

Biotech founders often make this error: chasing funds based on cheque size alone. Instead:

• Vet experience in life sciences.
• Seek strategic value (lab partnerships, distribution contacts).
• Check typical investment ticket size and follow-on appetite.

Your ideal SEIS/EIS backer brings more than money. They bring networks and sector expertise.

Step 5: After Funding: Compliance and Growth

Congrats, you’ve raised your SEIS/EIS funding. Now keep HMRC happy:

• Issue Compliance Statements (Form SEIS1/EIS1) within two years of share issue.
• Maintain Records of investor details, certificates and share registers.
• Report R&D Claims against your R&D spend to maximise additional tax credits.

Use your new capital to reach key milestones: proof of concept, clinical phases, partnerships. Keep investors in the loop with quarterly updates.

Oriel IPO: Your SEIS/EIS Funding Partner

Oriel IPO is more than just a marketplace. It’s a one-stop resource for biotech SEIS/EIS funding:

• Commission-free platform: No cut of funds raised, just straightforward subscription fees.
• Curated and vetted deals: Quality assurance before you pitch.
• Educational resources: Guides, webinars and expert insights to demystify every step.
• Investor connections: Angel groups, specialist VCs and corporate partners in one place.

By using Oriel IPO, you streamline admin, reduce cost and focus on what matters most—science and scale.

Tips and Pitfalls: What to Watch Out For

Avoid these common SEIS/EIS traps:

1. Underestimating Timelines
   Application, assurance and fundraise can easily take 3–6 months. Plan accordingly.

2. Neglecting IP Rights
   Clarity on IP ownership is critical. Disputes later can derail your exit.

3. Overvaluing Early
   Inflated valuations deters SEIS/EIS investors and risks HMRC rejection.

4. Wrong Investor Match
   Not all angels or VCs understand biotech timelines. Pick those who do.

Oriel IPO’s expert-led webinars and template decks help you dodge these bullets.

What Founders Are Saying

“Using Oriel IPO’s SEIS/EIS marketplace cut our fundraise time in half. We tapped into a network of life-science angels who really get biotech.”
— Dr Sarah Patel, CEO of Genova Biotech

“Oriel IPO’s commission-free model meant we kept every pound of our seed round. Their step-by-step guides were a lifesaver for our first SEIS application.”
— Alex Morgan, Co-founder of BioSense Diagnostics

Conclusion: Your Path to a Thriving Biotech Startup

Navigating biotech SEIS funding and EIS schemes may seem daunting, but with clear steps and the right partner, it becomes manageable. From eligibility checks to post-investment compliance, each phase has its own set of tasks. The Oriel IPO platform brings everything under one roof—curated investors, educational tools and a transparent fee structure—to help you focus on breakthroughs rather than bureaucracy.

Ready to power your biotech dream with SEIS/EIS funding? Explore biotech SEIS funding options on Oriel IPO now